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Abstract Fibulin-2 has previously been considered as a
marker to distinguish rat liver myofibroblasts from hepatic
stellate cells. The function of other fibulins in acute or
chronic liver damage has not yet been investigated. The
aim of this study has been to evaluate the expression
of fibulin-1 and -2 in models of rat liver injury and in
human liver cirrhosis. Their cellular sources have also been
investigated. In normal rat liver, fibulin-1 and -2 were both
mainly present in the portal field. Fibulin-1-coding tran-
scripts were detected in total RNA of normal rat liver,
whereas fibulin-2 mRNA was only detected by sensitive,
real-time quantitative polymerase chain reaction. In acute
liver injury, the expression of fibulin-1 was significantly
increased (17.23-fold after 48 h), whereas that of fibulin-2
was not modified. The expression of both fibulin-1 and -2
wasincreasedinexperimentalratlivercirrhosis (19.16-and
26.47-fold, respectively). At the cellular level, fibulin-1
was detectable in hepatocytes, “activated” hepatic stellate
cells, and liver myofibroblasts (2.71-, 122.65-, and 469.48-
fold over the expression in normal rat liver), whereas
fibulin-2 was restricted to liver myofibroblasts and was
regulated by transforming growth factor beta-1 (TGF-
β1) in 2-day-old hepatocyte cultures and in liver
myofibroblasts. Thus, fibulin-1 and -2 respond differen-
tially to single and repeated damaging noxae, and their
expression is differently present in liver cells. Expres-
sion of the fibulin-2 gene is regulated by TGF-β1i nl i v e r
myofibroblasts.
Keywords Carbontetrachloride.Extracellularmatrix.
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Introduction
Liver fibrogenesis represents the uniform response of the
liver to toxic, infectious, or metabolic agents and is
characterized by an increased synthesis and altered depo-
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nents (Ramadori et al. 1998). In liver fibrosis, the
composition in expanded portal areas, septa, and cirrhotic
nodules is similar to that of the normal portal tracts and
consists of collagens, various members of the structural
glycoprotein family, the major subclasses of glycosaminogly-
cans, and elastin. In addition to these classical matrix
components, members of the coagulation system, such as
fibrinogen/fibrin, plasmin, and von Willebrand factor (vWF;
Knittel et al. 1995;N e u b a u e re ta l .1995), participate in
hepatic tissue repair. The deposition of fibrin/fibronectin
seems to be an early event in hepatic injury (Neubauer et al.
1995) and might provide a pacemaker function during liver
fibrogenesis (Martinez-Hernandez 1985). However, the exact
temporal sequence of ECM protein deposition still needs to
be clarified, and possibly even the list of the main ECM
proteins involved in the repair processes is still incomplete.
The fibulins are an emerging family of ECM proteins
characterized by tandem arrays of calcium-binding epidermal
growth factor (EGF)-like domains and a unique C-terminal
structure (Timpl et al. 2003) and are a broadly conserved
component of the ECM (Hesselson and Kimble 2006). They
were first discovered in 1989 (see Argraves et al. 2003). To
date, fibulin-1 and -2 represent those characterized in more
detail (Timpl et al. 2003) and have been shown to display
distinct, yet overlapping, molecular interactions and expres-
sion patterns, whereas fibulins 3-6 are less-well defined
(Argraves et al. 2003). Both fibulin-1 and -2 are localized in
basement membranes, elastic fibers, and other connective
tissue structures. Fibulin-1 is also a plasma protein, and its
gene-expression can be detected early during embryonic
development in most basement membranes. Expression of
the fibulin-2 gene is initiated later during embryonic
development and is distributed in a more restricted manner
than that of fibulin-1 (Zhang et al. 1996).
Considerable evidence is available supporting a role for
fibulins within the ECM; indeed, they have been found in
various tissues in association with elastic fibers, basement
membrane networks, fibronectin microfibrils, and proteo-
glycan aggregates (Roark et al. 1995; Sasaki et al. 1995a, b;
Reinhardt et al. 1996; Timpl et al. 2003; Argraves et al.
2003).
Mammalian fibulin-1 has been shown to be an important
component of blood vessel walls and to be a ligand for a
diverse group of extracellular proteins (Argraves et al.
2003). Fibulin-2 is present in the basement membrane and
stroma of many tissues, and its expression pattern suggests
an essential role in organogenesis, particularly in embryonic
heart development (Tsuda et al. 2001). Recently, fibulin-2
has been shown to be produced by smooth muscle cells, as
a response to injury, and may participate in the ECM
organization that regulates the migration of smooth muscle
cells during the repair of vessel walls (Strom et al. 2006).
We have previously reported the identification and cellular
expression of fibulin-2, as a marker of alpha-smooth muscle-
actin
+ (SMA
+) myofibroblasts (MFs) in rat liver (Knittel et
al. 1999a). Fibulin-2-positive MFs have been detected in the
portal field, vessel walls, and hepatic parenchyma of the
normal liver, and their number is increased in the septal
regions during liver fibrogenesis (Knittel et al. 1999b).
Little is known about the hepatic localization and
expression of fibulin-1 in normal adult liver (Zhang et al.
1996), and no data are available concerning fibulin-1 and -2
in human liver diseases. The inflammatory response to liver
damage involves an important participation of the ECM
(Ramadori 1991; Knittel and Ramadori 1994; Baumann and
Gauldie 1994; Desmouliere and Gabbiani 1994;G r e s s n e r
and Bachem 1995; Pinzani 1995) and fibrogenetic processes.
Furthermore, the hepatic cellular sources of fibulin-1 based
on the study of liver cell cultures have not been described as
yet. In particular, whether fibulin-1 shares with fibulin-2 a
specificity for SMA
+ MFs remains to be investigated. Hence,
we have carried out a comparative investigation of the gene
expression and localization of fibulin-1 and -2 in normal
liver, during short term liver injury, in cirrhotic livers, and in
various types of liver cell culture.
Materials and methods
Animals
Liver cells were isolated from female Wistar rats (Charles
River, Sulzfeld, Germany) maintained under 12-h light/
dark cycles, with food and water being provided ad libitum.
In carrying out the in vivo experiments described in this
report, all animals received humane care in compliance
with the institutions’ guidelines and those of the National
Institutes of Health.
Reagents
Chemicals were obtained from the following sources:
Dulbecco’s modification of Eagle’s medium (DMEM),
M199 medium, and fetal calf serum (FCS) from Flow
Laboratories (Bonn, Germany); endothelial cell basal
medium (ECBM), human basic fibroblast growth factor
(hbFGF), and human EFG from PromoCell (Heidelberg,
Germany); pronase E from Merck (Darmstadt, Germany);
collagenase from Clostridium histolyticum (used for hepa-
tocyte isolations), random prime labeling kit, and dNTPs
from Boehringer (Mannheim, Germany); insulin S from
Hoechst (Frankfurt, Germany). Nycodenz was from Nye-
gaard (Oslo, Norway). Collagenase type I, collagen type I
(from rat tail), transforming growth factor beta-1 (TGF-β1)
repared from human platelets, and dexamethasone were
450 Cell Tissue Res (2009) 337:449–462from Sigma (Munich, Germany).
35S-labeled dATP,
32P-
dCTP, nick translation kit, and Hybond N membranes were
obtained from Amersham Buchler (Braunschweig, Ger-
many). Reagents for the random arbitrarily primed (RAP)
polymerase chain reaction (PCR) were from Stratagene
(Heidelberg, Germany), Moloney murine leukaemia virus
reverse transcriptase and first-strand synthesis buffer were
purchased from Gibco BRL (Karlsruhe, Germany). The TA
cloning kit, MMLV reverse transcriptase, and Sybr Green
reaction master mix were purchased from Invitrogen (San
Diego, Calif., USA). The DNA sequencing kit was from
Perkin Elmer (Foster City, Calif., USA).
Antibodies
The mouse antibodies (mAb) against alpha smooth muscle
actin (SMA) and the tetramethylrhodamine isothiocyanate
(TRITC)- or fluorescein isothiocynate (FITC)-conjugated
anti-mouse and anti-rabbit IgGs were from Sigma (Munich,
Germany). The Alexa (488 and 555)-conjugated anti-mouse
and anti-rabbit IgGs were from Invitrogen. The rabbit Ig to
human vWF (factor VIII) was from Dako (Copenhagen,
Denmark). Rabbit Ig directed against human fibronectin
were purchased from Boehringer Mannheim (Mannheim,
Germany). The rabbit IgG directed against mouse fibulin-
1C (Sasaki et al. 1995a), against mouse fibulin-2 (Pan et al.
1993a, b) and human fibulin-2 (Sasaki et al. 1995b) were as
previously described. Double-staining was performed for
fibulin-1/-2 and vWF by indirect immunofluorescence.
Induction of acute and chronic liver damage
Rats were given carbon tetrachloride (CCl4)/maize oil
solution (50% vol/vol) by oral administration as previously
described (Knittel et al. 1992a; Neubauer et al. 1995, 1996).
the CCl4 dosage was 75 μl/100 g body weight. Control
animals were treated with maize oil only. In each group,
animals were killed at 3, 6, 9, 12, 24, 48, 72, and 96 h after
a single high-dose of CCl4. The liver was perfused with
saline solution (0.9% NaCl) and snap-frozen in liquid
nitrogen. Massive liver necrosis was observed 24–48 h after
a single dose of CCl4. The necrotic areas were more
conspicuous in zone 3 Rappaport.
For the induction of liver fibrosis, chronic damage, and
regeneration, animals (male and female Wistar rats weigh-
ing approximately 200 g) were exposed to an oral
application of CCl4 once a week for a period of 12 to
17 weeks. At the end of the treatment, the liver was
removed and snap-frozen in liquid nitrogen. The frozen
specimens were used for RNA isolation and immunohisto-
chemical studies (Dudas et al. 2009). For acute liver injury,
three series were analyzed, whereas for chronic liver injury,
five series were investigated.
Human liver tissue
Three specimens of normal human livers were obtained
from non-cancerous tissue, surrounding surgically resected
liver metastases. Three specimens of cirrhotic human livers
were obtained from patients undergoing transplantation for
advanced viral cirrhosis. Specimens were frozen in liquid
nitrogen immediately after surgical removal. The study
protocol was in accordance with the Declaration of Helsinki
and approved by the local ethical committee.
Immunochemistry and cytochemistry
Frozen tissue sections (7 μm) of normal or acutely or
chronically damaged rat liver specimens and of normal and
cirrhotic human livers were fixed in methanol/acetone (5 min/
10 s at -20°C), air-dried for 45 min, and stored at -20°C, as
described elsewhere (Knittel et al. 1992a, b, 1996a, b;
Ramadori et al. 1990, 1991). Cells cultured in LAB-TEK
slide chambers were fixed by the same procedure. Cells or
tissue sections were examined by indirect immunochemistry.
Slides were preincubated with goat serum for 45 min at
37°C to reduce unspecific staining. After extensive washes
in phosphate-buffered saline (PBS), cells or tissue sections
were incubated with specific primary antibodies for 1 h at
37°C in a humidified atmosphere and washed three times
with PBS. Samples were covered with peroxidase- or
fluorescent-compound-conjugated secondary antibodies for
1 h at 37°C followed by extensive washes in PBS. The
secondary antibodies used were: anti-rabbit Alexa-555
(Molecular Probes, Karlsruhe, Germany; excitation
555 nm, emission 565 nm), anti-rabbit-FITC (Sigma,
Steinheim Germany; excitation 494 nm, emission 518 nm),
and anti-rabbit-TRITC (Sigma; excitation 557 nm, emission
576 nm). For indirect immunofluorescence, samples were
mounted with Fluoromount (Southern Biotechnology, Bir-
mingham, Ala., USA). When peroxidase-labeled secondary
antibodies were used, tissue sections were incubated with
PBS containing diaminobenzidine (0.5 mg/ml) and H2O2
(0.01%) solution, counterstained in Meyer’s hemalum, and
washed again before being covered with a coverslip. Anti-
bodies were diluted in PBS containing 0.1% bovine serum
albumin. Non-specific staining was controlled by incubation
with isotype-specific control rabbit or mouse IgGs instead of
the specific primary antibodies.
cDNA probes
Fibulin-1 A 274-bp-long cDNA generated by reverse
transcription with the PCR (RT-PCR) in rat liver MF-
derived samples was employed for Northern blot analysis.
Primers for the RT-PCR were designed by using the
program “prime” of the Wisconsin package of the genetics
Cell Tissue Res (2009) 337:449–462 451computer group (Devereux et al. 1984)a sf o l l o w s :f o r w a r d
primer, 5′-GTA TTC ATA ACT GCC CCC-3′; reverse
primer, 5′-CAC TCA TCC ACA TCA ACA C-3′,
corresponding to the published nucleotide sequence of the
mouse mRNA for fibulin-1, positions 935 and 1208 (AC
X70854; Pan et al. 1993a). This tract is situated in the EGF-
like repeats region, which is highly preserved in various
mammals, such as humans and mice (Pan et al. 1993a, b)
and is common to all the variants of fibulin-1 (Pan et al.
1993a;T r a ne ta l .1997b). The PCR product, expected to
encode the corresponding EGF-like repeats tract of the rat
sequence for fibulin-1, was cloned into pCR2.1 cloning
vector by using the TA cloning kit and sequenced. The
obtained sequence showed a 97.4% homology with the
mouse fibulin-1 sequence.
Fibulin-2 The 504-bp-long cDNA fragment generated by
the differential display method in rat MF (Knittel et al.
1999a) was used as a probe. Rat fibulin-2-specific
messengers were detected by Northern blot hybridization
as a large band at the position of 28S RNA, as found in
mouse (Neubauer et al. 1996).
In addition, to confirm the specificity of this probe, a
second probe generated by cloning RT-PCR products was
produced. The specific primers for the PCR were designed
(Devereux et al. 1984) from the conserved tract of the
mouse fibulin-2 sequence (AC X75285; Pan et al. 1993a)
coding for the EGF-like repeats. The primers were as
follows: forward primer, 5′-ATC TCC CAA CAC CAT
CCC AC-3′; reverse primer, 5′-TAT AGC CCT CTG CAC
ACA GCA C-3′, corresponding to positions 2024-2289 of
the mouse sequence (AC X75285). An annealing temper-
ature of 60°C was used. This second probe gave the same
results as the original on Northern blot hybridizations,
confirming the specificity for fibulin-2 of the probe
generated by the differential mRNA display procedure.
Fibronectin Clone pFH154 was used to detect fibronectin-
specific transcripts. It hybridizes to fibronectin messengers
of 7.1 kb and has been described in detail elsewhere
(Kornblihtt et al. 1984).
Glyceraldehyde-3-phosphate-dehydrogenase To validate
Northern blot results, a clone carrying rat glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH) cDNA (Fort et al.
1985) was used.
Probe labeling cDNA probes were
32P-labeled by random
priming (fibulin-1, fibulin-2, and GAPDH) or nick transla-
tion (fibronectin); the
32P-labeled dCTP was purchased from
Amersham (Munich, Germany) and had a specific activity
3000 Ci/mmol. For hybridization, a solution activity of
10
6 dpm/ml was used.
Cell isolation and culture
Rat hepatic stellate cells (HSCs), endothelial cells (ECs),
and Kupffer cells of the liver (KCs) were isolated and
purified as described previously (Knittel et al. 1992a, b,
1996a; Ramadori et al. 1990, 1991; Neubauer et al. 1995).
Briefly, the liver was digested enzymatically with pronase
and collagenase, and non-parenchymal liver cells were
separated by a Nycodenz density gradient. HSCs were
collected from the white top layer of the gradient. KCs and
ECs were further purified by centrifugal elutriation accord-
ing to Knook et al. (1977) and De Leeuw et al. (1983). By
using a JE-6B elutriation rotor in a J2-21 centrifuge
(Beckman Instruments, Palo Alto, CA) at 2500 rpm, KCs
were removed at 55 ml/min and ECs at 19 ml/min. HSCs,
KCs, and ECs were plated at a density of 2.5×10
5 (HSCs)
or 5×10
5 (KCs) cells per milliliter culture medium in 24-
well Falcon plates, in 1 ml medium/well, or on LAB-TEK
chamber slides (Nalge Nunc International, Naperville, Ill.,
USA), in 0.5 ml medium/well. They were cultured in
DMEM (HSCs), ECBM (ECs), or M199 (KCs) supple-
mented with 10% FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 1% L-glutamine. ECBM was additional-
ly supplemented with 0.05% insulin, hbFGF (1 ng/ml), and
hEGF (0.1 ng/ml).
Furthermore, freshly isolated HSC were plated for
7 days, released from the culture plates by trypsinization,
and replated at a 1:4 split ratio. Passaged HSC were
analyzed at confluency, which usually took place within
7 days (1st passage). The purity of the freshly isolated cells
and cultured cells was assessed as stated earlier (Knittel et
al. 1992a, 1996a, b, c, 1997b). Rat liver MFs were obtained
by the outgrowth of primary non-parenchymal liver cell
cultures.
Additional liver was digested as for the isolation of
KCs and ECs, and the remaining procedures were also
the same, except that, during stirring in the final enzyme-
containing solution, the pH was not corrected to
physiological levels in order to eliminate HSC. Finally,
at the time of the centrifugal elutriation, a fraction
enriched with MFs was collected at a flow rate of
23 ml/min. This fraction was plated in 24-well Falcon
plates (Becton Dickinson, Heidelberg, Germany) at a
density of 5×10
5 cells per well in 1 ml culture medium.
Cells were cultured in DMEM supplemented with 15%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and
1% L-glutamine. At confluency, which was usually
reached within 7–10 days, cells were released from the
culture plates by trypsinization and replated at a 1:4 split
ratio onto 24-well Falcon plates, in 1 ml medium/well, or
on LAB-TEK chamber slides, in 0.5 ml medium/well.
MFs were again passaged by using the same experimental
conditions at confluency; they were subcultured for
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being performed with MFs of passages 1–6.
Hepatocytes were isolated by in situ perfusion of the rat
liver with a collagenase-containing solution according to
Seglen (1972) and Ramadori et al. (1983) and plated onto
collagen-coated 6-well Falcon plates (Becton Dickinson) at
6.5×10
5 cells/ml, in 2 ml culture medium per well.
Hepatocytes were suspended in DMEM containing 10%
FCS for the first 4-6 h and 0.05% insulin plus 0.2% bovine
serum albumin later.
The culture medium was replaced at 4-6 h (hepato-
cytes), 1 day (KCs and ECs), 2 days (HSCs), or 6-7 days
(MFs) after plating and then every day in the case of
hepatocytes, ECs, and KCs, every other day for HSCs,
and twice a week for MFs. Cells were maintained in
culture at 37°C under a 5% CO2/95% O2 atmosphere and
100% humidity.
To evaluate the purity of the cultures, HSCs were
assessed by direct cell-counting methods, under a phase-
contrast microscope, by intrinsic vitamin A autofluor-
escence (HSCs; Ramadori et al. 1987) and, at days 2 and
7 after plating, were tested by immunofluorescence for the
presence of desmin, SMA, vWF, ED2, and albumin as
stated earlier (Knittel et al. 1992a, b). HSC cultures
showed only <3% contamination with KCs (ED2
[CD163]-positive cells, resident macrophages); ECs and
hepatocytes were not detectable. As assessed by immuno-
cytochemistry and light microscopy, freshly isolated
hepatocytes were at least 99% pure and showed only a
low (approximately 1%) contamination with non-
parenchymal liver cells. Until day 3 of culture, <1%
contaminating desmin- and/or SMA-positive cells were
detected in hepatocyte monolayers. During this period,
hepatocytes maintained albumin positivity revealed by
immunoprecipitation and Northern blot analysis. KCs
cultures were more than 99% pure. ECs were contaminat-
ed with 2% HSC and with 8%-10% KCs.
During primary culture, a transformation from a so-
called “quiescent”/“at an early stage of activation” HSC to
an “activated” HSC, exhibiting characteristics common to
smooth muscle cells and MFs, is observed (Ramadori et al.
1990; Ramadori 1991; Gressner and Bachem 1995; Pinzani
1995; Knittel et al. 1996a, b, c; Friedman 1996). By using
morphology and SMA immunoreactivity as an activation
parameter (Ramadori et al. 1990; Rockey et al. 1992),
HSCs were found to be fully “activated” (MF-like
morphology and 100% SMA-positive) at day 7 of primary
culture. HSCs cultured for 2 days were mainly SMA-
negative (<5% SMA-positive cells) and star-shaped and
were classified as HSCs “quiescent”/“at an early stage of
activation”.
All experiments were performed at least three individual
times with tests for the three different cell preparations.
Stimulation of hepatocytes, HSCs, and MFs with TGF-β1
Hepatocytes at day 1 after isolation, HSCs at day 2 and day
7 after plating, and MFs at the first and fourth passages at
confluency were washed three times with Gey’s balanced
salt solution and incubated for 20 h in serum-reduced (0.3%
FCS) culture medium alone or with TGF-β1 (at 0.1 or 1 ng/
ml). The concentration of cytokine used was previously
shown to have no cytotoxic effects (Knittel et al. 1997a).
RNA extraction and Northern blot analysis
Total RNA of HSCs, KCs, hepatocytes, and MFs was
extracted from cell cultures at various time-points (days 2
and 7 after plating in the case of HSC, days 1 and 3 for
KCs and hepatocytes, and from the 1st to 6th passage for
MF) and, in the case of HSCs, ECs, KCs, and hepatocytes,
also from freshly isolated cells. Liver cells were lysed with
guanidium isothiocyanate, and total RNA was extracted as
described elsewhere (Knittel et al. 1992a, b). Whole rat
tissues were lysed in guanidium isothiocyanate by means of
mechanical homogenization, and total RNA was extracted
as for cell cultures. Total RNA was resolved by agarose gel
electrophoresis, transferred to nylon membranes, and
hybridized with the cDNA probes described below. Total
RNA (5 μg) from cellular cultures or RNA (10 μg)
extracted from tissues was loaded onto each lane. Hybrid-
ization was performed for 2 h at 68°C by using the
QuickHyb Kit (Stratagene, La Jolla, Calif.). Post-
hybridization washes were performed twice for 10 min
each at room temperature and once for 2-10 min at 60°C in
2× standard saline citrate containing 0.1% SDS. Nylon
filters were washed, dried, and exposed to X-ray films at
-80°C. After adequate exposure (24-48 h for normal
exposure and 2-3 weeks for extended exposure), the filters
were washed in hot 1 M TRIS-EDTA buffer and then
rehybridized. Hybridizations were performed with fibulin-
1, fibulin-2, and fibronectin probes and finally with
GAPDH.
Northern blot results shown in figures are representative
of several independent experiments.
Real-time RT-PCR
Reverse transcription of isolated total RNA was performed
with MMLV reverse transcriptase (Invitrogen), according to
the instructions of the manufacturer. Real-time PCR
analysis of reverse (cDNAs) transcripts was performed
with the Abi Prism Sequence Detection System 7000
(Applied Biosystems, Foster City, Calif., USA) following
the manufacturer’s instructions, with the Sybr-green reac-
tion master mix (Invitrogen) and primers described else-
where (Dudas et al. 2007). For detection of rat fibulin-1, the
Cell Tissue Res (2009) 337:449–462 453following primer sequences were used: forward, TTC CTG
AGG AGG AAC AA; reverse, CCA CTG TGT TGA TGC
AGG AT.
Primers were synthesized by MWG Biotech (Ebersberg,
Germany) or by Invitrogen. The quantity of the PCR
products of the genes of interest was determined based on
the threshold PCR-cycle values (Ct-value), following the
instructions of Applied Biosystems and was normalized
with the quantities of the endogenous control (ubiquitin-C)
PCR product (Raddatz et al. 2005).
The ubiquitin-C expression was not affected by the
treatments in the investigated isolated cells and animal
models. The normalized quantities of fibulin-1 and fibulin-2
PCR products from treated animals were related to the values
from control animals, and the relative expression was plotted
against the observation time. In the isolated cells, the
expression levels were determined by absolute quantification.
In all cases, two or more series were analyzed in duplicate.
Statistical significance (P<0.05) was tested with Student’s
t-test and one-way analysis of variance.
Results
Distribution of fibulin-1 and -2 in normal rat liver
Fibulin-1 in normal rat livers was localized in the vessels of
portal spaces (Fig. 1) and central veins. No positivity for
fibulin-1 was visible along the sinusoids. In accordance
with published data (Knittel et al. 1999a, b; Tateaki et al.
2004), fibulin-2 immunoreactivity was low and was
detectable in the portal space (Fig. 1).
Distribution of fibulin-1 and -2 in acute liver damage in rat
The distribution of fibulin-1 and -2 was analyzed in the CCl4
model. Livers were studied from 3 h onward until 96 h
following CCl4 application, with an increase of fibulin-1
being most visible at 48 h after CCl4 administration (Fig. 2f).
On the contrary, fibulin-2 expression was not modified
by the acute liver injury and remained limited to the
periportal space (Fig. 2g-l).
Fig. 1 Localization of extracel-
lular matrix (ECM) proteins by
peroxidase (a, c, e) or fluores-
cent (b, d) staining in normal rat
livers around a portal space.
Fluorescent staining is shown to
illustrate double-labeling of the
same section. a Fibulin-1.
b Fibulin-2. c Fibronectin.
d Von Willebrand factor (vWF).
e Negative control. Bile ducts
negative for fibulin-1, fibulin-2,
and vWF (bold white arrows)
and positive for fibronectin
(black arrowheads) are indicat-
ed. Fibulin-1 and 2 are manifest
in the vessel walls. Fibronectin
stains the whole portal area and
sinusoidal spaces. vWF stains
the walls of portal vessels and
shows a scattered distribution in
the parenchyma. Bars 100 µm
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Fibulin-1 and -2 immunohistochemical staining increased
after sequentially repeated CCl4 treatments. Specific anti-
body against fibulin-1 stained all the septa uniformly, both
the smaller and larger ones, whereas the parenchyma
became positive to a lower extent, and the sinusoids
showed a weaker reaction (Fig. 3a, b). Fibronectin was
also immunostained in the septa and sinusoids (Fig. 3c, d).
The fibrotic septa appeared fibulin-2-positive (Fig. 3g, h).
Immunostaining for fibulin-2 was also evident at the border
between the scars and the parenchyma (Fig. 3g, h). The
sinusoidal spaces were also occasionally positive with a
scattered distribution (Fig. 3g, h). Fibulin-2 and vWF often
showed co-localization (Fig. 3g-j).
Normal and cirrhotic human livers
The specific staining for fibulin-1 and -2 was restricted to
portal spaces (Fig. 4a, b) and central veins in normal human
livers, similar to those in rat. In human cirrhosis, both
fibulins were uniformly present in the septa and, at a low
extent, also along the sinusoids (Fig. 4c, d); in particular,
fibulin-2 showed a more extended localization than in the
rat fibrotic livers and than fibulin-1 (Fig. 4c).
RNA analysis of normal and diseased rat livers
Northern blot analysis of total RNA from normal rat
liver showed traces of fibulin-1-coding transcripts
(Fig. 5). Two fibulin-1 transcripts corresponding to those
Fig. 2 Fibulin-1 and -2 immu-
nohistochemical localization in
CCl4-induced acute rat liver
injury. Immunofluorescent
labeling (red) of fibulin-1 (a-f)
or fibulin-2 (g-l) in control rat
liver (a, g), and 3 h (b, h), 6 h
(c, i), 12 h (d, j), 24 h (e, k),
and 48 h (f, l) after CCl4-gavage
(blue DAPI staining of nuclei).
Original magnification: 200×.
Bars 100 µm
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proteins by peroxidase (a-f) and
fluorescent (g-j) immunostain-
ing in fibrotic rat livers (CCl4
model). a, b Fibulin-1. c, d
Fibronectin. e, f Negative con-
trol. g, h Fibulin-2. i, j vWF. g–j
Double-staining of the same
section. Right Enlargement (2×)
of the main zone of interest in
the corresponding left image
(black arrowheads positivity
along sinusoids, white arrows
positivity along portal vessels).
Bars 100 µm
456 Cell Tissue Res (2009) 337:449–462expected in humans and mice, namely at 2.4 kb and
2.7 kb, were detected, coding respectively for the C and D
variants of fibulin 1 (Pan et al. 1993a;T r a ne ta l .1997a).
Fibulin-2-specific mRNAs were undetectable by Northern
blot analysis of total RNA from normal rat liver, even after
prolonged exposures of the films (normal exposure:
24-48 h; prolonged exposure: 2-3 weeks).
The quantification of fibulin-1- and fibulin-2-specific
transcripts was carried out by real-time RT-PCR. The
mRNA expression for fibulin-1 and fibulin-2 showed the
following pattern: after 48 h, the expression of fibulin-1-
specific transcripts considerably increased (17.23-fold
r e l a t e dt oc o n t r o l ;F i g .5 bottom, Fig. 6a). Fibulin-2
remained undetectable even after prolonged exposures of
the films; nevertheless, by real-time RT-PCR, fibulin-2
was detected in normal rat liver and after acute liver injury
and did not show significant changes in gene expression
(Fig. 6a, Table 1).
In total RNA from fibrotic rat livers, the expression of
fibulin-1-coding transcripts was 19.16-fold increased
compared with normal rat liver (Fig. 5 top, Fig. 6b,
Table 1). The specific mRNAs for fibulin-1 at 2.7 kDa
appeared more intense than those at 2.4 kDa in liver
cirrhosis (Fig. 5 top), whereas their intensity was similar at
the peak-late times (72 h) after acute liver injury (Fig. 5
bottom). By real-time RT-PCR, both fibulin-1 and fibulin-
2 were significantly upregulated (19.16 and 26.47-fold,
respectively) after repeated liver injury (Fig. 6b, c,
Table 1).
Cellular localization of fibulin-1 and -2
In order to characterize the cellular sources of fibulin-1 and
-2, the expression of these ECM proteins was studied by
Northern blot analysis and real-time RT-PCR in various rat
Fig. 4 Expression of fibulin-1
(b, d) and -2 (a, c) in normal
(a, b) and cirrhotic (c, d) human
livers (a, c immunofluorescence
staining, b, d peroxidase stain-
ing). In normal liver, fibulin-1
and -2 expression is restricted to
portal spaces (black arrowhead
positivity for fibulin-1 in the
portal vessel wall). In cirrhotic
human liver, fibulin-1 positivity
along sinusoids is scarce (black
curved arrows), but scars are
homogeneously positive. Simi-
larly, fibulin-2 is homogeneous-
ly positive in the scars, and
weak positivity is present along
capillarized sinusoids (white
curved arrows). Bars 100 µm
Fig. 5 Top Northern blot analysis of transcripts specific for fibulin-1
(double-bands at 2.4 and 2.7 kb corresponding, respectively, to the C
and D variants) in control (Ctrl) and fibrotic (Fibrosis) rat livers (CCl4
model). Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was
used as a control of the RNA loading in the lane. No specific
transcripts for fibulin-2 were detectable, even at much more prolonged
exposures of the film (A, B). Bottom Northern blot analysis of fibulin-
1 specific mRNAs after acute liver injury
Cell Tissue Res (2009) 337:449–462 457liver cell populations. Fibulin-1-specific transcripts were
detectable in cultured hepatocytes and in MFs (Table 2).
They were absent from freshly isolated ECs, from KCs at
all time-points, and from “quiescent”/“early stage of
activation” HSCs (day 2 after plating) but were induced
in fully “activated” HSC (day 7; Fig. 7,T a b l e2).
Isolated hepatocytes, activated HSCs, and MFs expressed
higher levels of fibulin-1 than normal rat liver (2.71-fold,
122.65-fold, and 469.48-fold, respectively).
Fibulin-2-specific transcripts were present in large
amounts in MFs (1518-fold over the level of the normal
rat liver) at all the passages tested. They were represented
3.1-fold over the expression level of normal liver in
activated HSCs as shown by real-time RT-PCR (Table 2).
Fibulin-2 appeared as a large band with a size of the 28S
ribosomal RNA in the total RNA isolate of rat liver MFs on
Northern blots (Fig. 7). The large band is consistent with
the existence of at least two different mRNA transcripts in
rat cells, as reported in mice, where it is hypothesized to be
attributable to the presence or absence of a single EGF-like
repeat (Pan et al. 1993b).
HSCs either freshly isolated or at day 2 after plating,
hepatocytes and KCs either freshly isolated or at day 1 and
3 of primary cultures, and ECs freshly isolated were also
analyzed by Northern blot hybridization. No fibulin-2
mRNA expression was revealed, even after prolonged
exposures of the films (Fig. 7).
The expression of fibulin-1-specific transcripts in fully
“activated” HSCs was not modified significantly by
stimulation with TGF-β1 (Table 2); fibulin-2 gene expres-
sion was also not increased in HSC significantly after TGF-
β1 exposure (Table 2). TGF-β1 induced a significant
4.33-fold increased gene expression for fibulin-2 in
hepatocyte cultures and a 2.62-fold increase in MF cultures
(Table 2). TGF-β1 had no effect on fibulin-1-coding
mRNA in isolated rat hepatocytes or MFs (Table 2).
Collectively, the immunocytochemistry and Northern
blot data indicated that the ECM proteins, fibulin-1 and
Fig. 6 Fibulin-1 and fibulin-2 relative mRNA expression in livers of
single CCl4-treated rats (a), at the indicated time points after
treatment, related to corn-oil-treated controls analyzed by real-time
reverse transcription with the PCR. Comparison of fibulin-1 (b) and
fibulin-2 (c) relative mRNA expression in livers after 48 h of single
CCl4 treatment and after 16 weeks of repeated CCl4 treatment. The
graphs plotted represent three independent treatment series after acute
liver injury and five independent treatment series after chronic liver
injury, in duplicate
Table 1 Changes in mRNA expression for fibulin-1 and fibulin-2
related to the expression level of control rat liver (given as the fold
change) shown by real-time reverse transcription with the PCR (RT-
PCR) in acute and chronic liver damage. Ubiquitin-C was used as an
endogeneous control. The expression levels in treated livers were
compared with controls by Student’s t-test
Samples Fibulin-1, fold change P-value (t-test) Fibulin-2, fold change P-value (t-test)
Control 1±0.70 - 1±0.38 -
Acute 6 h 0.67±0.27 0.455 0.13±0.09 0.447
12 h 1.63±0.67 0.312 0.23±0.09 0.177
24 h 4.21±3.19* 0.008 0.34±0.01 0.274
48 h 17.23±0.97** 10
-8 1.18±0.97 0.077
72 h 2.72±0.95 0.23 0.98±0.19 0.055
Chronic 16 weeks 19.16±8.84** 4.9×10
-5 26.47±1.42** 3.3×10
-4
*,**Significant changes
458 Cell Tissue Res (2009) 337:449–462-2, deposited in a fibrillar matrix, are synthesized in larger
amounts by rat liver MFs than in other cell populations.
Discussion
Fibulins, like other ECM molecules, are associated with
liver fibrosis, but their specific role is not fully understood.
Moreover, the main liver cell population promoting the
process of liver fibrogenesis remains uncertain (Ramadori
and Saile 2002). No definitive evidence has been found for
a “transdifferentiation” of HSCs to MFs. On the contrary,
an increasing amount of data support the conviction that
HSCs and MFs represent two similar but non-identical cell
populations, the latter being comparable with those of other
organs (Kinnman et al. 2003; Forbes et al. 2004).
In previous work, we first identified fibulin-2 as a
specific marker of rat liver MFs in order to be able to
distinguish these cells from other fibrogenic liver cell
populations such as HSCs (Knittel et al 1997a, c). The
present study aims to evaluate, in more detail, the
expression patterns of fibulin-1 and -2. Both proteins are
present in the elastic fibers of normal hepatic vessels, in rat
and in humans, according to previous publications (Roark
et al. 1995; Zhang et al. 1995; Miosge et al. 1996, 1998).
Following acute liver damage, fibulin-1-specific mRNAs
increase early after CCl4 administration and peak at
48 h (Figs. 5, 6). Interestingly, similar changes have not
been seen for fibulin-2, whose specific mRNA levels and
immunohistochemical expression remain unmodified
throughout the observed kinetics of acute tissue damage
and repair. Such divergent patterns of fibulin-1 and -2
might be related to the different properties of the two
proteins and to the participation of different subsets of cell
populations in the acute and chronic repair processes, at
least in rats. In particular, the participation of hepatocytes in
the synthesis of fibulin-1, which is also a circulating plasma
protein, can be suggested. In addition, the peak of gene
expression for fibulin-1 occurs 48 h after the CCl4
administration, when pericentral necrosis is detectable. At
this time point, the maximal stimulation of HSCs might be
expected. Fully activated HSC significantly contribute to
fibulin-1 synthesis in the liver (Fig. 7. Table 2). Moreover,
in view of the fibulin-2 pattern and the hypothesis of the
participation of different subsets of cell populations, it is
noteworthy that activated HSCs remain negative for fibulin-
2 after acute damage, whereas other molecules selectively
expressed by activated HSC, such as neural cell adhesion
molecule and glial fibrillary acidic protein, are reported to
appear at the immunohistochemical level under the same
conditions (Neubauer et al. 1996).
For the first time, we have shown that fibulin-1 and -2
are major components of the fibrotic septa not only in
animal models, but also in humans and that their gene
Table 2 mRNA expression levels of fibulin-1 and fibulin-2 in hepatic
stellate cells (HSC), hepatocytes (HC), and myofibroblasts (MF) related
to the expression level in control rat liver (in fold difference) by real-
time RT-PCR (TGFβ1 transforming growth factor beta-1). Beta-actin
was used as an endogeneous control. The expression levels in TGF-β1-
treated cells were compared with control cells by Student’s t-test
Samples Fibulin-1, fold difference P-value (t-test) Fibulin-2, fold difference P-value (t-test)
HSC, day 7 Control 122.65±22.36 - 3.10±0.61 -
1 ng/ml TGFβ1 138.95±33.39 0.243 13.12±8.94 0.316
HC Control 2.71±0.91 - 0.12±0.09 -
1 ng/ml TGFβ1 2.37±0.54 0.280 0.52±0.34* 0.027
MF, passage 2 Control 469.48±57.28 - 1517.99±24.25 -
1 ng/ml TGFβ1 463.65±52.79 0.462 3988±898.04* 0.027
*Significant changes
Fig. 7 Northern blot analysis of fibulin-1-specific (double-bands at
2.4 and 2.7 kb, corresponding respectively to the C and D variants)
and fibulin-2-specific transcripts (left) in the total RNA extracted from
hepatocytes at day 3 (Hep), hepatic stellate cells (HSC) at day 2 (d2)
and day 7 (d7) and Kupffer cells at day 3 (KC) after plating and from
myofibroblasts (MFs) at the first passage (MF 1P) and in the same
transcripts (right) studied in MFs at the fourth passage (MF 4P) before
(Ctrl) and after stimulation with transforming growth factor beta-1
(TGFβ-1) at two different concentrations (0.1 and 1n g / m l ).
Hybridization with GAPDH cDNA probe was used as an endoge-
neous control
Cell Tissue Res (2009) 337:449–462 459expression increases in liver fibrosis. Fibulin-1 stains both
small and large septa homogeneously in rats. Fibulin-2,
instead, shows a distribution, within the scars, that is not as
uniform as the pattern for fibulin-1. Usually, the smallest
septa are completely immunostained for fibulin-2. Larger
septa are, instead, immunostained for fibulin-2 preferential-
ly around portal vessels running inside them and along the
outer lining of the scars. Specific staining for fibulin-2
occasionally appears along the sinusoids in rats and rather
constantly and extensively in humans (Fig. 4).
The fibulin-2 positivity in this area is unexpected when
one considers that HSC primary cultures have been found
to stain negatively for fibulin-2, only limited cell groups
showing a positive reaction. As regards the origin of the
fibulin-2-positive cells in HSC cultures, the spotted
distribution of fibulin-2 positivity has inspired us to
consider fibulin-2-positive cells as being MFs contaminat-
ing HSC cultures, rather than a subpopulation of HSC
(Knittel et al. 1999a, b). Possible explanations for peri-
sinusoidal fibulin-2 detection, especially in human liver
cirrhosis, are that “activated” HSC behave differently in
vitro and during chronic damage in vivo, or that HSCs and
liver MFs constitute a mixed population during chronic
damage in vivo. However, as far as acute liver injury is
concerned, the in vitro and in vivo patterns are closely
correlated; in particular, no fibulin-2 expression is apparent,
consistent with HSC being the principal mesenchymal cell
type deputed to acute hepatic tissue repair.
In human liver cirrhosis, a greater induction of fibulin-2
has been detected than in the rat liver cirrhosis. This finding
is consistent with the previous observations that more MFs
might be present in human liver and in human liver
cirrhosis (Dudas et al. 2009).
An additional finding of our study is that the relative
increase of the two fibulin-1 variants C and D is not
identical during acute and chronic hepatic tissue repair.
After acute liver injury, the increase of the two isoforms is
similar, whereas in chronic liver damage, a prevalence of
isoform D is manifest. As shown by the analysis of in vitro
cultures, the fibulin-1 gene is expressed in a greater number
of cell types than is fibulin-2, including both parenchymal
and non-parenchymal cells. The synthesis of ECM proteins
in hepatocytes has been previously reported (Chojkier et al.
1988) and raises the question of the role of parenchymal
cells in the process of fibrogenesis (Dooley et al. 2008).
Nevertheless, we should also take into consideration that
primary cultures of isolated hepatocytes might be over-
grown by mesenchymal cells, and the contaminating cell
populations might express ECM proteins. Similar to other
matrix proteins, fibulin-1 transcription is greatly enhanced
in fully “activated” MF-like HSCs (day 7 after plating) with
respect to HSCs “at an early stage of activation” (day 2
after plating; Ramadori 1991; Gressner and Bachem 1995;
Pinzani 1995; Knittel et al. 1996a, b, c; Friedman 1996),
further confirming the role of activated HSCs in fibulin-1
deposition in chronic hepatic tissue repair. The gene
expression for fibulin-1 is not regulated by the fibrogenic
mediator TGFβ1 in any of the liver cells (hepatocytes,
HSCs, and MFs) that express it, whereas fibulin-2 is
responsive to TGF-β1, at least in MFs. This confirms that
fibulin-2-positive cells are not a more advanced fibrogenic
subphenotype of HSCs. A low increase of the gene
expression of fibulin-2 in hepatocyte cultures treated with
TGFβ1 might be also attributable to contaminating MFs
(Table 2).
In conclusion, these in vitro data confirm our previous
results showing that HSCs and liver MFs are two similar,
but non-identical, cell populations of the hepatic mesen-
chymal compartment. The participation of various liver cell
populations in matrix synthesis might be different after
acute and chronic liver injury. An understanding of the
interactions among the different liver cell populations and
their roles in the production of different ECM proteins
might open up new and interesting perspectives in the field
of liver fibrogenesis
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